DRESS Syndrome (Pulmonary Involvement)

1. Comprehensive Executive Overview: Understanding DRESS Syndrome

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome, classified under ICD-10 code L51.2, is a severe, life-threatening idiosyncratic drug reaction. While classically defined by a triad of fever, rash, and internal organ involvement, pulmonary involvement represents one of the most clinically challenging manifestations of this condition.

When DRESS syndrome affects the lungs, it transitions from a dermatological emergency to a complex systemic inflammatory crisis. Pulmonary involvement occurs in approximately 10–30% of DRESS cases and can manifest as interstitial pneumonitis, pleuritis, or acute respiratory distress syndrome (ARDS). Because the symptoms often mimic common viral or bacterial infections, delayed diagnosis is a significant risk factor for increased mortality. This guide serves as a clinical resource for understanding the pathophysiology, diagnostic pathways, and therapeutic management of pulmonary-involved DRESS syndrome.

2. Pathophysiology, Etiology, and Risk Factors

Etiology

DRESS syndrome is primarily a delayed-type hypersensitivity reaction (Type IVb). Unlike common allergic reactions, DRESS has a prolonged latency period, typically appearing 2 to 8 weeks after the initiation of the offending medication. Common causative agents include:

• Anticonvulsants: Carbamazepine, Phenytoin, Lamotrigine, Phenobarbital.
• Antibiotics: Sulfonamides, Vancomycin, Minocycline.
• Antivirals: Abacavir.
• Uricosuric agents: Allopurinol.

Pathophysiology

The underlying mechanism involves a complex interplay between drug-specific T-cell activation and viral reactivation.
1. Drug-T-cell Interaction: The drug metabolite binds to HLA molecules on the surface of antigen-presenting cells, activating CD4+ and CD8+ T-cells.
2. Viral Reactivation: DRESS is unique in its frequent association with the reactivation of Human Herpesvirus 6 (HHV-6), Epstein-Barr Virus (EBV), and Cytomegalovirus (CMV). This "viral trigger" exacerbates the inflammatory cascade.
3. Pulmonary Damage: In pulmonary involvement, the infiltration of eosinophils and activated T-lymphocytes into the alveolar interstitium and pleura leads to cytokine-mediated tissue damage. This inflammatory milieu results in the clinical features of interstitial lung disease (ILD) or pneumonitis.

Risk Factors

• Genetic Predisposition: Specific HLA alleles (e.g., HLA-B*58:01 for allopurinol) significantly increase risk.
• Immunocompromised State: Patients with underlying viral loads are at a higher risk of systemic reactivation.
• Polypharmacy: Simultaneous use of multiple high-risk medications.

3. Signs, Symptoms, and Clinical Presentation

The clinical presentation of DRESS with pulmonary involvement is often insidious. Patients typically present with systemic signs before pulmonary symptoms become overt.

Pulmonary-Specific Presentation

Patients may initially present with mild exertional dyspnea. As the inflammatory process progresses, physical examination may reveal fine inspiratory crackles (Velcro-like rales) upon auscultation. In severe cases, patients may develop respiratory failure requiring mechanical ventilation.

4. Standard Diagnostic Evaluation & Workup

The diagnosis of DRESS is based on the RegiSCAR criteria, which assesses the probability of the syndrome.

Diagnostic Workup Components

1. Laboratory Assays:
   • Complete Blood Count (CBC): To identify eosinophilia and atypical lymphocytes.
   • Liver and Renal Function Panels: To assess multi-organ involvement (ALT/AST, Creatinine).
   • Viral Serology: PCR testing for HHV-6, EBV, and CMV to confirm reactivation.
2. Imaging:
   • Chest X-ray: May show non-specific interstitial opacities or pleural effusions.
   • High-Resolution Computed Tomography (HRCT): The gold standard for pulmonary involvement. Findings often include ground-glass opacities, interlobular septal thickening, and centrilobular nodules.
3. Biopsy:
   • Skin Biopsy: Shows perivascular lymphocytic infiltrate with eosinophils.
   • Transbronchial Biopsy (if indicated): Used to rule out opportunistic infections or malignancy if the patient fails to respond to corticosteroids.

RegiSCAR Scoring System

• Definite: Score > 5.
• Probable: Score 4–5.
• Possible: Score 2–3.

5. Therapeutic Interventions

Management of DRESS syndrome with pulmonary involvement requires a multidisciplinary approach, typically involving Pulmonology, Dermatology, and Intensive Care.

Pharmacotherapy

• Immediate Withdrawal: The primary step is the absolute discontinuation of the suspected causative agent.
• Systemic Corticosteroids: The cornerstone of treatment. High-dose intravenous methylprednisolone (1–2 mg/kg/day) is standard until clinical improvement, followed by a very slow taper over several weeks or months. Rapid tapering often leads to "rebound" phenomena.
• Immunomodulators: In refractory cases or when steroid-sparing agents are needed, IVIG (Intravenous Immunoglobulin) or Cyclosporine may be utilized.

Supportive Care

• Oxygen Therapy: Supplemental oxygen or non-invasive ventilation (NIV) to maintain arterial oxygen saturation.
• Nutritional Support: Ensuring high caloric intake due to the hypermetabolic state induced by systemic inflammation.
• Skin Care: Topical corticosteroids and emollient therapy for dermatological symptoms.

Long-term Prognosis

The prognosis depends on the severity of organ involvement. While the rash and hematological markers usually resolve within weeks, pulmonary involvement may leave residual scarring (fibrosis). Long-term follow-up with Pulmonary Function Tests (PFTs) is essential to monitor for the development of chronic restrictive lung disease.

6. Frequently Asked Questions (FAQ)

1. Is DRESS syndrome contagious?
No. DRESS syndrome is a non-infectious, idiosyncratic immune reaction to medication. It cannot be transmitted from person to person.

2. How long does it take for pulmonary symptoms to appear?
Pulmonary involvement usually occurs within 2 to 8 weeks after starting the drug, but it can sometimes present later as the inflammatory process progresses.

3. What is the gold standard for diagnosing pulmonary involvement in DRESS?
HRCT (High-Resolution Computed Tomography) is the gold standard for visualizing the extent of interstitial lung inflammation.

4. Can I ever take the medication that caused my DRESS syndrome again?
Absolutely not. Re-exposure to the offending agent can trigger a rapid, severe, and potentially fatal recurrence.

5. Why is a slow steroid taper necessary?
DRESS syndrome is characterized by a prolonged inflammatory phase. Tapering steroids too quickly often leads to a recurrence of symptoms, known as a "DRESS flare."

6. Are there specific genetic tests for DRESS?
Yes, for certain drugs (like Allopurinol), testing for specific HLA alleles (e.g., HLA-B*58:01) can help identify patients at high risk before prescribing.

7. Does the lung damage from DRESS usually heal?
With prompt treatment, most patients recover fully. However, severe cases can lead to permanent pulmonary fibrosis if not treated early.

8. What is the role of viral testing in DRESS?
Viral testing (HHV-6, EBV, CMV) confirms systemic viral reactivation, which is a hallmark of DRESS and helps differentiate it from other drug eruptions.

9. Can DRESS be treated at home?
No. Due to the high risk of multi-organ failure and respiratory compromise, DRESS syndrome requires hospitalization and close monitoring by specialists.

10. What long-term follow-up is needed?
Patients require serial Pulmonary Function Tests (PFTs), blood work, and follow-up with a pulmonologist to monitor for late-onset lung complications.